Citation:Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al 2012

From Cancer Guidelines Wiki

Citation


Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012 Jul 28;380(9839):358-65 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22735384.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?Cecilia Taingcompleted
Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?Meghna Kakanicompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Chemotherapy for melanoma
  2. Immunotherapy for melanoma
  3. Targeted therapies for melanoma